By Erica Westly | October 26, 2009
As many news outlets have noted, vaccine manufacturers have been having trouble meeting the U.S. demand for H1N1 vaccines. The delays are largely due to the fact that most drug companies have been relying on traditional egg-based techniques for producing vaccines. There are new, faster production techniques available, but the FDA has yet to approve them for use in the U.S. I’ve written a few blog posts about this issue for Fast Company. Unfortunately, these delays might hinder the already difficult task of persuading Americans to get vaccinated (51 percent of respondents to a recent poll said they didn’t plan to get vaccinated; 40 percent they didn’t plan to vaccinate their children either).
Comments are closed.